Loading...
•
Sep 30, 2020
Quanterix Q3 2020 Earnings Report
Quanterix reported a strong quarter of growth driven by advances in Alzheimer's, MS, and COVID testing.
Key Takeaways
Quanterix announced financial results for Q3 2020, highlighting a strong quarter of growth despite pandemic-related headwinds. The company launched new Neurology assays, secured an NIH contract for SARS-CoV-2 Antigen test development, entered a non-exclusive IVD license agreement with Abbott, initiated surveillance studies, and raised nearly $100 million in capital.
Made advances in Alzheimer’s, MS and COVID testing.
Launched Neurology assays including pTau-181 and a comprehensive N4PE four plex.
Secured an $18.2M NIH RADx contract to accelerate development, manufacturing scale-up and deployment of novel high-throughput SARS-CoV-2 Antigen test.
Entered a non-exclusive IVD license agreement with Abbott.